Drug Study
DRUG NAME |DOSAGE |CLASSIFICATION |Mechanism of action |INDICATION |CONTRAINDICATION |Nursing
Implication | |Brand name :
Hemostan
Fibrinon, Cyklokapron, Lysteda, Transamin
Generic name:
Tranexamic acid
|500 mg. /tab ID
8x a times a day. |
Anti-fibrinolytic, antihemorrhagic
|
Tranexamic acid is a synthetic derivative of the amino acid lysine. It exerts its antifibrinolytic effect through the reversible blockade of lysine-binding sites on plasminogen molecules. Anti-fibrinolytic drug inhibits endometrial plasminogen activator and thus prevents fibrinolysis and the breakdown of blood clots. The plasminogen-plasmin enzyme system is known to cause coagulation defects through lytic activity on fibrinogen, fibrin and other clotting factors. By inhibiting the action of plasmin (finronolysin) the anti-fibrinolytic agents reduce excessive breakdown of fibrin and effect physiological hemostasis. |
Hemorrhage following dental and/or oral surgery in patients with hemophilia
Management of hemophilic patients (those having Factor VIII or Factor IX deficiency) who have oral mucosal bleeding, or are undergoing tooth extraction or other oral surgical procedures.
Surgical: General surgical cases but most especially operative procedures on the prostate, uterus, thyroid, lungs, heart, ovaries, adrenals, kidneys, brain, tonsils, lymph nodes and soft tissues.
Obstetrical and gynecological: abortion, post-partum hemorrhage and menometrorrahgia
Medical: epistaxis, hemoptysis, hematuria, peptic ulcer with hemorrhage and blood dyscrasias with hemorrhage
Effective in promoting hemostasis in traumatic injuries.
Preventing hemorrhage after orthopedic surgeries. |Allergic reaction to the drug or hypersensitivity
Presence of blood clots (eg, in the leg, lung, eye, brain), have a history of blood clots, or are at risk for blood clots
Current administration of factor IX complex concentrates
Implication | |Brand name :
Hemostan
Fibrinon, Cyklokapron, Lysteda, Transamin
Generic name:
Tranexamic acid
|500 mg. /tab ID
8x a times a day. |
Anti-fibrinolytic, antihemorrhagic
|
Tranexamic acid is a synthetic derivative of the amino acid lysine. It exerts its antifibrinolytic effect through the reversible blockade of lysine-binding sites on plasminogen molecules. Anti-fibrinolytic drug inhibits endometrial plasminogen activator and thus prevents fibrinolysis and the breakdown of blood clots. The plasminogen-plasmin enzyme system is known to cause coagulation defects through lytic activity on fibrinogen, fibrin and other clotting factors. By inhibiting the action of plasmin (finronolysin) the anti-fibrinolytic agents reduce excessive breakdown of fibrin and effect physiological hemostasis. |
Hemorrhage following dental and/or oral surgery in patients with hemophilia
Management of hemophilic patients (those having Factor VIII or Factor IX deficiency) who have oral mucosal bleeding, or are undergoing tooth extraction or other oral surgical procedures.
Surgical: General surgical cases but most especially operative procedures on the prostate, uterus, thyroid, lungs, heart, ovaries, adrenals, kidneys, brain, tonsils, lymph nodes and soft tissues.
Obstetrical and gynecological: abortion, post-partum hemorrhage and menometrorrahgia
Medical: epistaxis, hemoptysis, hematuria, peptic ulcer with hemorrhage and blood dyscrasias with hemorrhage
Effective in promoting hemostasis in traumatic injuries.
Preventing hemorrhage after orthopedic surgeries. |Allergic reaction to the drug or hypersensitivity
Presence of blood clots (eg, in the leg, lung, eye, brain), have a history of blood clots, or are at risk for blood clots
Current administration of factor IX complex concentrates